Matched real-world MCL data shows acalabrutinib and zanubrutinib lower atrial fibrillation vs ibrutinib, with fewer bleeding events. (Of note, Janssen voluntarily withdrew ibrutinib from the US market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results